LEO Pharma

LEO Pharma initiates a Phase 2b dose-ranging clinical trial with an oral H4R antagonist in adult patients with moderate-to-severe atopic dermatitis (AD)

Share

BALLERUP, Denmark, December 14, 2021 -- LEO Pharma A/S, a global leader in medical dermatology, today announced it has enrolled the first patient in a Phase 2b dose-ranging clinical trial with an investigational oral histamine receptor 4 (H4R) antagonist (LEO 152020) for the potential treatment of adults with moderate-to-severe atopic dermatitis (AD).

Histamine is a key mediator of allergic inflammation.[i] Unlike histamine receptors 1-3, H4R plays a role in itch response and triggers the migration of cells in the immune system toward inflammatory and allergic sites throughout the body.[ii],[iii],[iv] As an oral H4R antagonist, LEO 152020 has the potential to prevent histamine-induced initiation of inflammatory and itch mechanisms via the histamine 4 receptor.[v]

The primary objective for the randomized, triple-blind, placebo-controlled, multi-center Phase 2b dose-ranging clinical trial is to evaluate the efficacy of LEO 152020 compared with placebo in the treatment of adults with moderate-to-severe AD.[vi]The primary endpoint of the trial is change in Eczema Area and Severity Index (EASI) from baseline to Week 16.vi Additional exploratory endpoints will evaluate patient-reported symptoms such as itch and sleeplessness.vi The number of treatment-emergent adverse events per patient from baseline to Week 16 defines the key safety endpoint of the trial.vi    

"Managing a skin disease such as atopic dermatitis with oral treatments is challenging because of limited available options for chronic use,” said Prof. Dr. med. Thomas Werfel, Dept. Dermatology and Allergy, Hannover Medical School, Hannover, Germany, and lead investigator of the Phase 2b clinical trial. “This trial will evaluate whether an alternative oral option can potentially offer a new choice for adult patients with moderate-to-severe AD.”

AD is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.[vii] AD is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.[viii]

“We have been encouraged by results on itch in pre-clinical studies with this investigational medicine for patients who prefer oral treatment options,” said Dr. Jörg Möller, Executive Vice President, Global Research & Development, LEO Pharma. “We are committed to developing innovative therapies that may help improve the lives of patients who need a wider range of treatment options and routes of administration for skin diseases.”

[i]   Jemima EA, et al. Mol Immunol. 2014;62:19-28.

[ii]   Thurmond RL. Frontiers Pharmacol. 2015;6:65.

[iii]Schaper‐Gerhardt K, et al. Br J Pharmacol. 2020;177:490-502.

[iv]Damaj BB, et al. J Immunol. 2007;179:7907-15.

[v] de Esch IJ et al. Trends Pharmacol Sci 2005;26:462-469.

[vi] ClinicalTrials.Gov: https://clinicaltrials.gov/ct2/show/NCT05117060 (Accessed November 2021).

[vii]Weidinger S, et al. Lancet. 2016; 387:1109-1122.

[viii]                              Boguniewicz M, et al. Immunol Rev. 2011;242(1):233-46.

Contacts

Maia Fredtoft Soechting
Global R&D Communications
+45 2681 4579
mfddk@leo-pharma.com

Henrik Heskjaer
Global External Communications
+45 3140 6180
hdtdk@leo-pharma.com

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO 152020

In 2018, LEO Pharma A/S and JW Pharmaceutical Corporation entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize LEO 152020 (LP0190/JW1601) for all non-ophthalmic indications worldwide, except in South Korea, where JW Pharmaceutical retains rights.

About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 billion.

For more information, please visit www.LEO-Pharma.com.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

Adtralza® (tralokinumab) achieves primary and secondary endpoints in Phase 3 trial of adolescents with moderate-to-severe atopic dermatitis22.10.2021 13:00:00 CEST | Press release

Sixteen-week results from the Phase 3 ECZTRA 6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved measures of efficacy compared to placebo1 Tralokinumab was generally well-tolerated with an overall frequency and severity of adverse events comparable with placebo, consistent with that observed in adults in Phase 3 trials1 BALLERUP, Denmark, October 22, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.1 The week 16 results from the Phase 3 ECZTRA 6 trial were shared during the 2021 Fall Clinical Dermatology Conference held virtually and with a hybrid option in Las Vegas. Tralokinumab is a high-affinity, human monoclonal antibody that specifically binds to and inhibits IL-13, a key driver of atopic dermatitis signs and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom